Pfizer Company Profile (NYSE:PFE)

About Pfizer (NYSE:PFE)

Pfizer logoPfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:PFE
  • CUSIP: 71708110
  • Web:
  • Market Cap: $215.29 billion
  • Outstanding Shares: 5,947,349,000
Average Prices:
  • 50 Day Moving Avg: $35.25
  • 200 Day Moving Avg: $33.76
  • 52 Week Range: $29.83 - $36.60
  • Trailing P/E Ratio: 26.48
  • Foreward P/E Ratio: 13.12
  • P/E Growth: 2.33
Sales & Book Value:
  • Annual Revenue: $52.35 billion
  • Price / Sales: 4.11
  • Book Value: $9.81 per share
  • Price / Book: 3.69
  • Annual Dividend: $1.28
  • Dividend Yield: 3.5%
  • EBITDA: $20.24 billion
  • Net Margins: 15.84%
  • Return on Equity: 24.51%
  • Return on Assets: 8.60%
  • Debt-to-Equity Ratio: 0.58%
  • Current Ratio: 1.34%
  • Quick Ratio: 1.06%
  • Average Volume: 17.16 million shs.
  • Beta: 1
  • Short Ratio: 2.37

Frequently Asked Questions for Pfizer (NYSE:PFE)

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Wednesday, September 27th. Stockholders of record on Friday, November 10th will be given a dividend of $0.32 per share on Friday, December 1st. This represents a $1.28 annualized dividend and a dividend yield of 3.54%. The ex-dividend date is Thursday, November 9th. View Pfizer's Dividend History.

How were Pfizer's earnings last quarter?

Pfizer, Inc. (NYSE:PFE) released its quarterly earnings results on Tuesday, August, 1st. The company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.02. The company earned $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business's revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the company posted $0.64 EPS. View Pfizer's Earnings History.

When will Pfizer make its next earnings announcement?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY17 earnings guidance on Tuesday, August, 1st. The company provided earnings per share guidance of $2.54-2.60 for the period, compared to the Thomson Reuters consensus estimate of $2.55. The company issued revenue guidance of $52-54 billion, compared to the consensus revenue estimate of $52.78 billion.

Where is Pfizer's stock going? Where will Pfizer's stock price be in 2017?

18 equities research analysts have issued 1-year price targets for Pfizer's shares. Their predictions range from $31.00 to $53.00. On average, they anticipate Pfizer's stock price to reach $38.20 in the next twelve months. View Analyst Ratings for Pfizer.

What are analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:

  • 1. According to Zacks Investment Research, "Pfizer is facing headwinds in the form of genericization of key drugs, lost alliance revenues, pricing pressure and rising competition which is hurting the top-line. Though Pfizer’s growing immuno-oncology portfolio offers strong potential, many of these assets are in early stage of development. Additionally, Pfizer’s shares have underperformed the industry this year so far. Nonetheless, we believe that new products like Ibrance, contribution from acquisitions, cost-cutting efforts and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential. Bavencio is being considered a key long-term growth driver for Pfizer. The company has a mixed record of earnings surprises in recent quarters. Estimates have remained stable ahead of its Q3 earnings results." (10/11/2017)
  • 2. BMO Capital Markets analysts commented, "We are highly confident the deal will close as the purchase agreement removes IP risk and development risks, and creates significant shareholder value. We believe there is minimal risk for the deal being blocked due to anti-trust considerations CTP-543 Phase IIa initiated with top-line results expected 1Q18. The phase IIa trial will enroll approximately 100 patients spread across 4 active arms of differing doses (4, 8, 12 and 16 mg BID) and a placebo comparator. The primary endpoint for the trial will be measured using the severity of alopecia tool (SALT) after patients undergo 24 weeks of dosing. An additional 28 weeks of dosing of CTP-543 is planned for all patients enrolled in the study. If successfully developed, we anticipate a significant pricing discount for CTP-543 relative to Jakafi – owned by Incyte (INCY, Non-Rated). The earlier delay to initiate the trial due to clinical supply delays, which lasted around 2 months, has been resolved." (4/27/2017)
  • 3. UBS AG analysts commented, " The FDA approved Novartis' CDK4/6 agent, Kisqali (ribociclib), in first-line treatment for HR+/HER2- metastatic breast cancer in combo with any aromatase inhibitor. Recall that MONALEESA-2 was stopped early, and while interim data demonstrated a reduction in risk of disease progression or death by 44% over letrozole alone, the mPFS had not been reached at the time. For the first time, the label presented a mPFS of 25.3 mos for Kisqali + letrozole vs 16 mos for letrozole alone. The 9.3 mos improvement over letrozole is essentially comparable to 10.3 mos improvement (24.8 mos for Ibrance vs 14.5 mos for letrozole) for Pfizer's Ibrance. Given the strong interim data that were comparable to Ibrance, we believe the approval of Kisqali was largely expected. Our takeaway: Label looks a little worse than Ibrance. Overall, we think the label looks slightly worse, particularly on safety. On the positive, the label is broader, as the indication is for use of Kisqali in combo with anyaromatase inhibitors (vs Ibrance in combo with letrozole). However, as the vast majority of first-line use letrozole, the broader label shouldn't meaningfully impact Ibrance, in our view. We're not clear on how Kisqali got the broader label, but we think this could be encouraging for Ibrance, as the Ibrance label could also become as broad with the potential April approval of the confirmatory Phase 3 PALOMA-2 (Ibrance was approved under an accelerated pathway with Phase 2 PALOMA-1 data). On safety, the Kisqali label warns of QT prolongation and liver tox, which are not in the Ibrance label. We think the QT issue could put Kisqali at a disadvantage. Thoughts on the stock: Shouldn't impact the stock much, if anyIbrance has been on the market for ~2 years and has made significant headway to becoming a standard of therapy, and we do not believe there was anything in the Kisqali label that would meaningfully impact the significant lead that Pfizer has. In our CDK4/6 model, we assign a 5% share for Kisqali in 2017 that goes to 15%, 18%, and 20% in 2018-2020E." (3/14/2017)
  • 4. Jefferies Group LLC analysts commented, "We wanted to highlight a key data catalyst in which a positive outcome can drive shares higher: PIIa data for XEN801 for mod-to-severe acne in the latter part of Q1 (JEF est: ~Mar). We continue to like the risk/reward going into the data, especially on the heels of Dermira’s positive PIIb data for DRM01, which operates on the same pathway but more upstream. Reiterating Buy and $13 PT. Highlighting Key PIIa Data Catalyst in Latter Part of Q1: We wanted to take the opportunity to highlight a key data catalyst in which a positive outcome can drive shares higher: topline PIIa data catalyst for XEN801 for moderate-to-severe acne in the latter part of Q1 (JEF estimate: ~Mar). We previously conducted a review on XEN801 in April ’16, which can be found here, and now that the data catalyst is drawing near, we wanted to take the chance to highlight it again. To recap, the PIIa trial is a randomized, double- blind, multicentre, vehicle-controlled trial evaluating the efficacy and safety of patients with moderate-to-severe acne. The trial will compare XEN801 topical gel (1%) and matching placebo gel for 12 weeks with a 4-week follow-up. XENE has randomized 165 patients (v. 150 that was planned at conception), and has 85% power (v. 80% previously) to detect a ~16% difference." (1/19/2017)

Are investors shorting Pfizer?

Pfizer saw a increase in short interest in the month of September. As of September 29th, there was short interest totalling 48,999,272 shares, an increase of 3.3% from the September 15th total of 50,665,014 shares. Based on an average daily trading volume, of 17,716,144 shares, the days-to-cover ratio is presently 2.8 days. Currently, 0.8% of the company's stock are sold short.

Who are some of Pfizer's key competitors?

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:

  • Ian C. Read, Chairman of the Board, Chief Executive Officer
  • Frank A. D'Amelio, Chief Financial Officer, Executive Vice President - Business Operations
  • Albert Bourla, Group President - Pfizer Innovative Health
  • Mikael Dolsten M.D., Ph.D., President - Worldwide Research and Development
  • John D. Young, Group President - Pfizer Essential Health
  • Rady A. Johnson II, Executive Vice President, Chief Compliance and Risk Officer
  • Douglas M. Lankler, Executive Vice President, General Counsel
  • Charles H. Hill III, Executive Vice President - Worldwide Human Resources
  • Freda C. Lewis-Hall M.D., Executive Vice President, Chief Medical Officer
  • Kirsten Lund-Jurgensen, Executive Vice President, President - Pfizer Global Supply

Who owns Pfizer stock?

Pfizer's stock is owned by many different of retail and institutional investors. Top institutional investors include Beacon Financial Group (0.01%), Park National Corp OH (0.01%), Neville Rodie & Shaw Inc. (0.00%), First National Bank of Mount Dora Trust Investment Services (0.00%), Osborn Williams & Donohoe LLC (0.00%) and Eqis Capital Management Inc. (0.00%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, John D Young, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson and Sally Susman. View Institutional Ownership Trends for Pfizer.

Who sold Pfizer stock? Who is selling Pfizer stock?

Pfizer's stock was sold by a variety of institutional investors in the last quarter, including Private Asset Management Inc., Bridges Investment Counsel Inc., Park National Corp OH, Osborn Williams & Donohoe LLC and Neville Rodie & Shaw Inc.. Company insiders that have sold Pfizer stock in the last year include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Frank A Damelio, Ian C Read, Laurie J Olson, Mikael Dolsten, Rady A Johnson and Sally Susman. View Insider Buying and Selling for Pfizer.

Who bought Pfizer stock? Who is buying Pfizer stock?

Pfizer's stock was acquired by a variety of institutional investors in the last quarter, including Beacon Financial Group, Curbstone Financial Management Corp, Eqis Capital Management Inc., Hefty Wealth Partners, First National Bank of Mount Dora Trust Investment Services and McQueen Ball & Associates Inc.. View Insider Buying and Selling for Pfizer.

How do I buy Pfizer stock?

Shares of Pfizer can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of Pfizer stock can currently be purchased for approximately $36.20.

MarketBeat Community Rating for Pfizer (NYSE PFE)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  853 (Vote Outperform)
Underperform Votes:  436 (Vote Underperform)
Total Votes:  1,289
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pfizer (NYSE:PFE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $38.20 (5.52% upside)
Consensus Price Target History for Pfizer (NYSE:PFE)
Price Target History for Pfizer (NYSE:PFE)
Analysts' Ratings History for Pfizer (NYSE:PFE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017Jefferies Group LLCSet Price TargetNeutral$38.00N/AView Rating Details
10/11/2017Deutsche Bank AGSet Price TargetBuy$38.00N/AView Rating Details
10/11/2017Barclays PLCSet Price TargetBuy$38.00N/AView Rating Details
10/10/2017BMO Capital MarketsSet Price TargetBuy$37.00N/AView Rating Details
9/20/2017Morgan StanleyUpgradeEqual Weight -> Overweight$35.00 -> $39.00LowView Rating Details
9/19/2017Sanford C. BernsteinSet Price TargetBuy$39.00LowView Rating Details
8/15/2017Berenberg BankReiterated RatingHold$39.00 -> $36.00LowView Rating Details
8/14/2017Cowen and CompanySet Price TargetBuy$43.00LowView Rating Details
7/20/2017Credit Suisse GroupDowngradeOutperform -> Neutral$38.00 -> $36.00LowView Rating Details
5/16/2017Citigroup Inc.DowngradeNeutral -> Sell$38.00 -> $31.00LowView Rating Details
3/23/2017Societe GeneraleReiterated RatingNeutral$36.00LowView Rating Details
2/2/2017Morningstar, Inc.Reiterated RatingBuyN/AView Rating Details
2/1/2017Atlantic SecuritiesSet Price TargetBuy$37.00N/AView Rating Details
1/21/2017Piper Jaffray CompaniesSet Price TargetBuy$53.00N/AView Rating Details
1/18/2017Goldman Sachs Group, Inc. (The)Set Price TargetNeutral$36.00N/AView Rating Details
12/2/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
11/7/2016Bank of America CorporationReiterated RatingBuy$40.00 -> $36.00N/AView Rating Details
11/2/2016ArgusDowngradeBuy -> HoldN/AView Rating Details
8/3/2016J P Morgan Chase & CoSet Price TargetBuy$40.00N/AView Rating Details
5/4/2016Independent Research GmbHSet Price TargetNeutral$37.00N/AView Rating Details
5/2/2016Leerink SwannLower Price TargetMarket Perform$37.00 -> $34.70N/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
2/16/2016SunTrust Banks, Inc.Lower Price TargetNeutral$37.00 -> $33.00N/AView Rating Details
1/26/2016Nord/LBReiterated RatingBuyN/AView Rating Details
11/24/2015Evercore ISIReiterated RatingBuy$38.00N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Pfizer (NYSE:PFE)
Earnings by Quarter for Pfizer (NYSE:PFE)
Earnings History by Quarter for Pfizer (NYSE PFE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017$0.64N/AView Earnings Details
8/1/2017Q2 2017$0.65$0.67$13.08 billion$12.90 billionViewListenView Earnings Details
5/2/2017Q1 2017$0.67$0.69$13.09 billion$12.78 billionViewListenView Earnings Details
1/31/2017Q416$0.50$0.47$13.64 billion$13.60 billionViewN/AView Earnings Details
11/1/2016Q3$0.62$0.61$13.05 billion$13.05 billionViewN/AView Earnings Details
8/2/2016Q216$0.62$0.64$13.01 billion$13.10 billionViewN/AView Earnings Details
5/3/2016Q116$0.55$0.67$12.00 billion$13.00 billionViewN/AView Earnings Details
2/2/2016Q415$0.52$0.53$13.57 billion$14.05 billionViewN/AView Earnings Details
10/27/2015Q315$0.51$0.60$11.56 billion$12.10 billionViewListenView Earnings Details
7/28/2015Q215$0.52$0.56$11.39 billion$11.00 billionViewListenView Earnings Details
4/28/2015Q115$0.49$0.51$10.79 billion$10.86 billionViewN/AView Earnings Details
1/27/2015Q414$0.53$0.54$12.94 billion$13.10 billionViewN/AView Earnings Details
10/28/2014Q314$0.55$0.57$12.24 billion$12.40 billionViewN/AView Earnings Details
7/29/2014Q214$0.57$0.58$12.49 billion$12.80 billionViewN/AView Earnings Details
5/5/2014Q114$0.56$0.57$12.07 billion$11.35 millionViewN/AView Earnings Details
1/27/2014Q413$0.52$0.56$13.35 billion$13.56 billionViewN/AView Earnings Details
10/29/2013Q313$0.56$0.58$12.69 billion$12.64 billionViewN/AView Earnings Details
7/30/2013Q2 2013$0.55$0.56$13.02 billion$12.97 billionViewListenView Earnings Details
4/30/2013Q1 2013$0.55$0.54$14.10 billion$13.50 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.44$0.47$14.40 billion$15.10 billionViewListenView Earnings Details
11/1/2012Q312$0.53$0.53$14.64 billion$14.00 billionViewN/AView Earnings Details
7/31/2012$0.54$0.62ViewN/AView Earnings Details
5/1/2012$0.57$0.58ViewN/AView Earnings Details
1/31/2012$0.47$0.50ViewN/AView Earnings Details
11/1/2011$0.55$0.62ViewN/AView Earnings Details
8/2/2011$0.59$0.60ViewN/AView Earnings Details
5/3/2011$0.59$0.60ViewN/AView Earnings Details
2/1/2011$0.46$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pfizer (NYSE:PFE)
2017 EPS Consensus Estimate: $2.51
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.67$0.67$0.67
Q2 20173$0.62$0.65$0.64
Q3 20172$0.60$0.61$0.61
Q4 20172$0.59$0.60$0.60
(Data provided by Zacks Investment Research)


Current Dividend Information for Pfizer (NYSE:PFE)
Next Dividend:12/1/2017
Annual Dividend:$1.28
Dividend Yield:3.54%
Dividend Growth:7.70% (3 Year Average)
Payout Ratio:94.12% (Trailing 12 Months of Earnings)
50.00% (Based on This Year's Estimates)
46.38% (Based on Next Year's Estimates)
Track Record:7 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Pfizer (NYSE:PFE)

Dividend History by Quarter for Pfizer (NYSE PFE)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Pfizer (NYSE:PFE)
Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 68.98%
Insider Trades by Quarter for Pfizer (NYSE:PFE)
Institutional Ownership by Quarter for Pfizer (NYSE:PFE)
Insider Trades by Quarter for Pfizer (NYSE:PFE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/12/2017Sally SusmanInsiderSell38,230$35.00$1,338,050.00View SEC Filing  
9/1/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00View SEC Filing  
8/31/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00View SEC Filing  
8/31/2017Frank A DamelioEVPSell94,409$34.00$3,209,906.00View SEC Filing  
8/31/2017Ian C ReadCEOSell197,168$34.00$6,703,712.00View SEC Filing  
8/21/2017Laurie J OlsonInsiderSell8,064$32.70$263,692.80View SEC Filing  
8/7/2017Alexander R MackenzieInsiderSell15,000$33.50$502,500.00View SEC Filing  
8/4/2017Ian C. ReadCEOSell96,950$34.00$3,296,300.00View SEC Filing  
3/10/2017Rady A JohnsonInsiderSell4,500$34.19$153,855.00View SEC Filing  
3/9/2017Charles H HillInsiderSell36,000$34.07$1,226,520.00View SEC Filing  
3/2/2017Mikael DolstenInsiderSell30,970$34.51$1,068,774.70View SEC Filing  
11/9/2016Anthony J MaddalunaInsiderSell10,000$33.00$330,000.00View SEC Filing  
11/4/2016Albert BourlaInsiderSell18,390$30.05$552,619.50View SEC Filing  
5/26/2016Frank A DamelioEVPSell100,000$34.49$3,449,000.00View SEC Filing  
5/24/2016Loretta V CangialosiVPSell86,000$33.97$2,921,420.00View SEC Filing  
5/11/2016Laurie J OlsonEVPSell4,700$33.50$157,450.00View SEC Filing  
5/10/2016Frank A DamelioEVPSell192,000$33.66$6,462,720.00View SEC Filing  
5/10/2016John D YoungInsiderSell41,700$33.53$1,398,201.00View SEC Filing  
5/9/2016Anthony J MaddalunaEVPSell8,950$33.75$302,062.50View SEC Filing  
5/9/2016Ian C ReadCEOSell275,000$33.80$9,295,000.00View SEC Filing  
5/5/2016Sally SusmanEVPSell76,116$33.75$2,568,915.00View SEC Filing  
5/4/2016Douglas M LanklerEVPSell29,700$33.69$1,000,593.00View SEC Filing  
5/4/2016Mikael DolstenInsiderSell67,588$33.46$2,261,494.48View SEC Filing  
5/3/2016Frank A DamelioEVPSell87,079$33.65$2,930,208.35View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.00View SEC Filing  
6/11/2015Laurie J OlsonEVPSell26,000$34.39$894,140.00View SEC Filing  
3/12/2015Sally SusmanEVPSell46,179$34.00$1,570,086.00View SEC Filing  
2/13/2015Loretta V CangialosiVPSell104,000$34.73$3,611,920.00View SEC Filing  
2/12/2015Anthony J MaddalunaEVPSell9,000$34.85$313,650.00View SEC Filing  
2/11/2015Frank A DamelioEVPSell14,800$34.30$507,640.00View SEC Filing  
2/10/2015Anthony J MaddalunaEVPSell9,000$33.78$304,020.00View SEC Filing  
12/8/2014Anthony J MaddalunaEVPSell6,500$32.00$208,000.00View SEC Filing  
11/10/2014Charles H HillEVPSell8,285$30.18$250,041.30View SEC Filing  
11/7/2014John D YoungInsiderSell21,600$29.89$645,624.00View SEC Filing  
10/29/2014Anthony J MaddalunaEVPSell2,425$29.56$71,683.00View SEC Filing  
6/12/2014Laurie J OlsonEVPSell36,275$29.53$1,071,200.75View SEC Filing  
6/2/2014Geno J GermanoInsiderSell30,000$29.68$890,400.00View SEC Filing  
3/17/2014John YoungInsiderSell9,000$31.38$282,420.00View SEC Filing  
3/4/2014Loretta CangialosiVPSell102,943$32.05$3,299,323.15View SEC Filing  
3/4/2014Mikael DolstenInsiderSell35,789$32.58$1,166,005.62View SEC Filing  
3/4/2014Sally SusmanEVPSell67,585$32.59$2,202,595.15View SEC Filing  
1/13/2014Frank DamelioEVPSell131,810$30.82$4,062,384.20View SEC Filing  
11/1/2013Anthony J MaddalunaEVPSell43,500$31.02$1,349,370.00View SEC Filing  
11/1/2013Loretta V CangialosiVPSell10,000$31.20$312,000.00View SEC Filing  
10/28/2013Ian C ReadCEOSell338,000$30.57$10,332,660.00View SEC Filing  
9/16/2013Freda Lewis-HallEVPSell38,461$28.70$1,103,830.70View SEC Filing  
7/31/2013Charles H HillEVPSell96,500$29.64$2,860,260.00View SEC Filing  
7/31/2013Loretta V CangialosiVPSell14,688$29.63$435,205.44View SEC Filing  
5/15/2013Amy W SchulmanEVPSell70,000$29.36$2,055,200.00View SEC Filing  
5/15/2013Ian C ReadCEOSell69,900$29.39$2,054,361.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Pfizer (NYSE:PFE)
Latest Headlines for Pfizer (NYSE:PFE)
DateHeadline logoSuit: US Firms' Bribes Funded Iraq Militia Attacks on Americans - - October 17 at 9:02 PM logoThis hot trade is about to get even hotter: Trader - October 17 at 9:02 PM logoAerie (AERI) Up on FDA Review Committee Result for Rhopressa - October 17 at 9:02 PM logoThe Blockbuster That Wasn't -- A CETP Inhibitor Post-Mortem - October 17 at 3:59 PM logoPfizer: Trial Of ALK-Inhibitor Lorlatinib Shows Clinically Meaningful Activity - October 17 at 6:16 AM logo[$$] Drugstore Favorites May Be Catching the Common Consumer Cold - October 17 at 6:16 AM logoPfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer - October 17 at 6:16 AM logoPfizer, Inc. (PFE) Given a $38.00 Price Target at Jefferies Group LLC - October 16 at 9:44 AM logoBarclays PLC Analysts Give Pfizer, Inc. (PFE) a $38.00 Price Target - October 15 at 10:20 PM logoPfizer: Could a Big Merger Move the Needle? - October 14 at 6:42 AM logoPfizer Says It's Pondering a Big Sale - October 14 at 6:42 AM logo[$$] Pfizer Seen Mulling Options - October 13 at 8:00 AM logo2 Reasons Pfizer Is on Our Minds Today - October 13 at 1:49 AM logoDeutsche Bank AG Analysts Give Pfizer, Inc. (PFE) a $38.00 Price Target - October 12 at 10:38 PM logoPfizer: Who Will Pay $14B for Advil? - October 12 at 8:12 AM logoThree blue-chip US companies are on the verge of breaking apart, prodded by short-term investors - October 12 at 8:12 AM logoPfizer considers selling unit that includes Advil, ChapStick - October 12 at 8:12 AM logoIs Pfizer the Best Dividend Stock in Healthcare? - October 12 at 8:12 AM logoPfizer Consumer Unit Worth as Much as $14 Billion - October 12 at 8:12 AM logoCorporate News Blog - Pharma Giant Pfizer Mulling Divestment of Consumer Healthcare Business - October 12 at 8:12 AM logoU.S. FDA Approves LYRICA® CR (pregabalin) Extended-Release Tablets CV - October 12 at 8:12 AM logoPfizer, Inc. (PFE) Downgraded to "Hold" at Zacks Investment Research - October 11 at 11:02 PM logo3 Reasons Why Pfizer Investors Will Win With a Consumer Business Sale or Spinoff - October 11 at 8:31 AM logoPfizer, Inc. (PFE) PT Set at $37.00 by BMO Capital Markets - October 11 at 7:10 AM logoPfizer: Growth Trajectory Locked, Ready For Launch - Seeking Alpha - October 11 at 6:32 AM logoPfizer Inc. (PFE) May Spin Off Consumer Health Biz - - October 11 at 6:32 AM logoGoing Long Pfizer Inc. (PFE) Stock Is an Easy Pill to Swallow - - October 11 at 6:32 AM logoPfizer Inc. (PFE) May Spin Off Consumer Health Biz - October 10 at 6:31 PM logoStocks rise after strong forecasts from Wal-Mart, airlines - October 10 at 3:35 PM logoGoing Long Pfizer Inc. (PFE) Stock Is an Easy Pill to Swallow - October 10 at 11:18 AM logoPfizer considers consumer business sale - October 10 at 9:16 AM logoPfizer mulls options for consumer healthcare business - Reuters - October 10 at 8:28 AM logoPfizer is mulling sale, spin-off of its consumer health-care business - October 10 at 8:00 AM logoPfizer may sell consumer unit - October 10 at 7:16 AM logoThis Dow stock looks poised to ‘pull an Intel’ and break out to a multi-year high - October 10 at 12:07 AM logoZacks: Brokerages Anticipate Pfizer, Inc. (PFE) to Announce $0.64 EPS - October 8 at 2:12 AM logoPfizer, Inc. (PFE) Upgraded by ValuEngine to Buy - October 7 at 10:34 PM logoPfizer (PFE) Sell Ranking Confirmed - October 6 at 8:50 AM logoAlzheimer's Drug Discovery Foundation and Pfizer's Centers for Therapeutic Innovation Co-Fund New Alzheimer's Project - October 5 at 3:45 PM logoWhy Pfizer is the 'Top Dividend Stock of the Dow' With 3.5% Yield (PFE) - October 5 at 3:45 PM logoS.Africa watchdog drops over-charging probe into Aspen, Equity - October 5 at 3:45 PM logoPfizer Launches Novel Programs to Put Important Support Services at the Fingertips of Cancer Patients - October 5 at 3:45 PM logoStock Traders Buy High Volume of Pfizer Call Options (PFE) - October 5 at 1:48 AM logoInteresting November Stock Options for PFE - October 3 at 10:37 AM logoMarkets Move Higher; Inversion Rules Put Pfizer-Allergan Back In Focus -- ICYMI - October 3 at 10:37 AM logo3 Winning Dividend Strategies To Survive The Next Pullback - October 3 at 10:37 AM logoGender Focus Proves Rewarding for This ETF - October 3 at 10:37 AM logo[$$] Big Questions for Big Pharma - October 3 at 10:37 AM logoPfizer Inc. (PFE) Receives Average Recommendation of "Hold" from Analysts - October 2 at 2:58 AM logoPfizer Exposes the Sordid Underbelly of Drug Prices - October 1 at 7:57 AM



Pfizer (PFE) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.